IP Library Patent Application 17612100
Patent Application
App. No. 17/612,100

CANNABINOID-COMPRISING COMPOSITIONS FOR MANAGEMENT OF PAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/612,100
Abstract

There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject.

Claims (35)

1 . A composition comprising:

a purified cannabidiol (CBD) or a derivative thereof; and

an anti-inflammatory botanical extract comprising Arnica extract and Boswellia extract.

2 . The composition according to claim 1 , further comprising

at least one purified terpene or a derivative thereof.

3 . The composition according to claim 1 , wherein the composition is in a form suitable for topical administration to a subject.

4 .- 9 . (canceled)

10 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof is one or more of: bisabolol, cadinene, caryophyllene or beta-caryophyllene, camphor, capsaicin, carvacrol, copaene, farnesol, guaia-1 (10),11-diene, humulene, isoborneol, γ-linolenic acid, methyl salicylate, β-sitosterol, brassicasterol, stigmasterol, campesterol and γ-terpinene.

11 . (canceled)

12 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof comprises bisabolol.

13 .- 14 . (canceled)

15 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof comprises capsaicin.

16 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof comprises beta-caryophyllene.

17 . The composition according to claim 1 , wherein the purified cannabidiol or the derivative thereof is present in the composition in an amount between about 2 wt % and about 6 wt % of the total weight of the composition.

18 . (canceled)

19 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof is present in the composition in an amount between about 0.25 wt % and about 20 wt % of the total weight of the composition.

20 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof is present in the composition in an amount between about 0.25 wt % and about 8 wt % of the total weight of the composition.

21 .- 26 . (canceled)

27 . The composition according to claim 1 , wherein the composition comprises one or more of: Coco Caprylate: Polawax™ NF; Isopropyl myristate; MCT Oil; Ethylhexyl glycerin; Phenoxyethanol; Vitamin E; Polysorbate 60; Copaiba Balsam Essential Oil; Angelica Root Extract; Wild Yam Extract; Polysorbate 80; Span™ 60; Aloe Vera juice; EDTA Disodium Dihydrate; Sorbitol; Xanthan Gum; and Tazman Pepper™.

28 . The composition according to claim 1 , wherein the anti-inflammatory botanical extract is present in the composition in an amount of between about 0.5 wt % and about 90 wt % of the total weight of the composition.

29 .- 31 . (canceled)

32 . A method for management of pain in a subject, the method comprising administering the composition as defined in claim 1 to the subject.

33 . A method for alleviating pain in a subject, the method comprising administering the composition as defined in claim 1 to the subject.

34 . A method for treating pain in a subject, the method comprising administering the composition as defined in claim 1 to the subject.

35 .- 38 . (canceled)

39 . The composition according to claim 2 , wherein the at least one purified terpene or the derivative thereof comprises menthol, camphor, or a combination thereof.

40 . The composition according to claim 1 , wherein the purified cannabidiol or the derivative thereof is present in the composition in an amount between about 1 wt % and about 10 wt % of the total weight of the composition.

41 . The composition according to claim 1 , wherein the anti-inflammatory botanical extract is present in the composition in an amount of between about 5 wt % and about 10 wt % of the total weight of the composition.

42 . A composition for topical application comprising:

a purified cannabidiol (CBD) or a derivative thereof in an amount between about 1 wt % and about 10 wt % of the total weight of the composition; and

an anti-inflammatory botanical extract in an amount of between about 0.5 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory botanical extract comprises Arnica extract and Boswellia extract.

43 . A composition for topical application comprising:

a purified cannabidiol (CBD) or a derivative thereof;

an anti-inflammatory botanical extract in an amount of between about 0.5 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory botanical extract comprises Arnica extract and Boswellia extract; and

at least one purified terpene or a derivative thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST IN PATENT INTELLECTUAL PROPERTY Recorded Jan 9, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: CANOPY GROWTH CORPORATION
Reel/Frame 074281/0925 →
NOTICE OF GRANT OF SECURITY INTEREST Recorded Aug 15, 2024
From: CANOPY GROWTH CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 068654/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2022
From: HETHERINGTON, MARK
To: CANOPY GROWTH CORPORATION
Reel/Frame 060829/0948 →